Nineteenth Annual Pezcoller Symposium: Hypothesis-Driven Clinical Investigation in Cancer

^{1 1}Dana-Farber Cancer Institute, Boston, Massachusetts; ²Memorial Sloan Kettering Cancer Center, New York, New York; and ³Roswell Park Cancer Institute, Buffalo, New York

^* To whom correspondence should be addressed. E-mail: enrico.mihich{at}roswellpark.org.

	Abstract

This symposium was held in Trento, Italy, from June 14 to 16, 2007, and was cochaired by William G. Kaelin, Enrico Mihich, and Charles L. Sawyers. A session was deveted to the proof of concept derived from successes in target-oriented therapeutics. Molecular targets must be identified in each patients because they are equally present in all patients with the same tumor type. A session was devoted to the identification of markers of drug effectiveness. Two sessions were focused on opportunities for developing new specific molecular target-oriented therapies. [Cancer Res 2007;67(23):11102–5]

Key Words: Molecular targets, target mutations, signal transduction, suppressor genes, disease models